Stephen E Gitelman

13PUBLICATIONS
56CO-AUTHORS
Molecular targetsInfant and child healthMedical biochemistry - proteins and peptides (incl. medical proteomics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Aboriginal and Torres Strait Islander youth and family social and emotional wellbeing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 12, 2026
Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset.

Carmella Evans-Molina, Stephen E Gitelman, Andrea Mari

|Feb 25, 2026
How to communicate with individuals and caregivers at the time of presymptomatic type 1 diabetes diagnosis.

Korey K Hood, Amanda R Twigg, Stephen E Gitelman

|Jan 24, 2026
Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician-patient partnership for early care of chronic beta cell failure. Reply to Mallone R, Bandini A [letter].

Stephen E Gitelman, Kimber Simmons, Jennifer L Sherr

|Jan 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Carla J Greenbaum, S Alice Long, Stephen E Gitelman

|Jan 20, 2026
Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes.

Aye Khine, Srinath Sanda, Christine Torok

|Nov 06, 2025
Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.

Stephen E Gitelman, Kimber Simmons, Jennifer L Sherr

Pageof 3

Frequent Collaborators

5 joint publications

Linda A DiMeglio

4 joint publications

Carmella Evans-Molina

3 joint publications

Kevan C Herold

3 joint publications

Jennifer L Sherr